These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 28693495)

  • 1. An agent-based model of triple-negative breast cancer: the interplay between chemokine receptor CCR5 expression, cancer stem cells, and hypoxia.
    Norton KA; Wallace T; Pandey NB; Popel AS
    BMC Syst Biol; 2017 Jul; 11(1):68. PubMed ID: 28693495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer.
    Xiang L; Gilkes DM; Chaturvedi P; Luo W; Hu H; Takano N; Liang H; Semenza GL
    J Mol Med (Berl); 2014 Feb; 92(2):151-64. PubMed ID: 24248265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment.
    Chaturvedi P; Gilkes DM; Takano N; Semenza GL
    Proc Natl Acad Sci U S A; 2014 May; 111(20):E2120-9. PubMed ID: 24799675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis.
    Jin K; Pandey NB; Popel AS
    Breast Cancer Res; 2018 Jun; 20(1):54. PubMed ID: 29898755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial:mesenchymal stem cell signaling.
    Narayanan R; Ahn S; Cheney MD; Yepuru M; Miller DD; Steiner MS; Dalton JT
    PLoS One; 2014; 9(7):e103202. PubMed ID: 25072326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel antagonist of the CCL5/CCR5 axis suppresses the tumor growth and metastasis of triple-negative breast cancer by CCR5-YAP1 regulation.
    Chen L; Xu G; Song X; Zhang L; Chen C; Xiang G; Wang S; Zhang Z; Wu F; Yang X; Zhang L; Ma X; Yu J
    Cancer Lett; 2024 Feb; 583():216635. PubMed ID: 38237887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
    Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
    Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling triple-negative breast cancer heterogeneity: Effects of stromal macrophages, fibroblasts and tumor vasculature.
    Norton KA; Jin K; Popel AS
    J Theor Biol; 2018 Sep; 452():56-68. PubMed ID: 29750999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CCR5 blockage by maraviroc: a potential therapeutic option for metastatic breast cancer.
    Pervaiz A; Zepp M; Mahmood S; Ali DM; Berger MR; Adwan H
    Cell Oncol (Dordr); 2019 Feb; 42(1):93-106. PubMed ID: 30456574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion.
    Jiao X; Velasco-Velázquez MA; Wang M; Li Z; Rui H; Peck AR; Korkola JE; Chen X; Xu S; DuHadaway JB; Guerrero-Rodriguez S; Addya S; Sicoli D; Mu Z; Zhang G; Stucky A; Zhang X; Cristofanilli M; Fatatis A; Gray JW; Zhong JF; Prendergast GC; Pestell RG
    Cancer Res; 2018 Apr; 78(7):1657-1671. PubMed ID: 29358169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia regulates stemness of breast cancer MDA-MB-231 cells.
    Xie J; Xiao Y; Zhu XY; Ning ZY; Xu HF; Wu HM
    Med Oncol; 2016 May; 33(5):42. PubMed ID: 27038472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
    Ring A; Kaur P; Lang JE
    BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRIPTO antagonist ALK4
    Balcioglu O; Heinz RE; Freeman DW; Gates BL; Hagos BM; Booker E; Mirzaei Mehrabad E; Diesen HT; Bhakta K; Ranganathan S; Kachi M; Leblanc M; Gray PC; Spike BT
    Breast Cancer Res; 2020 Nov; 22(1):125. PubMed ID: 33187540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelial cells promote triple-negative breast cancer cell metastasis
    Zhang W; Xu J; Fang H; Tang L; Chen W; Sun Q; Zhang Q; Yang F; Sun Z; Cao L; Wang Y; Guan X
    FASEB J; 2018 Jan; 32(1):276-288. PubMed ID: 28899878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
    Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
    Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
    Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
    Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways.
    Singel SM; Batten K; Cornelius C; Jia G; Fasciani G; Barron SL; Wright WE; Shay JW
    Breast Cancer Res; 2014 Mar; 16(2):R28. PubMed ID: 24642040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Essential roles of the interaction between cancer cell-derived chemokine, CCL4, and intra-bone CCR5-expressing fibroblasts in breast cancer bone metastasis.
    Sasaki S; Baba T; Nishimura T; Hayakawa Y; Hashimoto S; Gotoh N; Mukaida N
    Cancer Lett; 2016 Aug; 378(1):23-32. PubMed ID: 27177471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted gene silencing of CCL2 inhibits triple negative breast cancer progression by blocking cancer stem cell renewal and M2 macrophage recruitment.
    Fang WB; Yao M; Brummer G; Acevedo D; Alhakamy N; Berkland C; Cheng N
    Oncotarget; 2016 Aug; 7(31):49349-49367. PubMed ID: 27283985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCL5-CCR5 interactions modulate metabolic events during tumor onset to promote tumorigenesis.
    Gao D; Cazares LH; Fish EN
    BMC Cancer; 2017 Dec; 17(1):834. PubMed ID: 29216863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.